Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts $11.05 +0.09 (+0.82%) As of 03:16 PM Eastern Add Compare Share Share Earnings Stock AnalysisChartEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock Astellas Pharma Earnings Summary Astellas Pharma released Q1 2026 earnings on July 30, 2025, reporting an EPS of $0.40, which beat analysts' consensus estimates of $0.14 by $0.26. Quarterly revenue was reported to be $3.41 billion, above analyst estimates of $3.20 billion. With a trailing EPS of $0.30 and a P/E Ratio of 36.83, Astellas Pharma's earnings are expected to grow 61.90% next year, from $0.42 to $0.68 per share. Q1 2026 Earnings ResourcesQ1 2026 Earnings ReportALPMY Upcoming EarningsAstellas Pharma's next earnings date is estimated for Wednesday, October 29, 2025, based on past reporting schedules. Upcoming Q2 Earnings DateOct. 29Before Market OpensEstimatedConsensus EPS (Jul. 30) $0.14 Actual EPS (Jul. 30) $0.40 Beat By $0.26 Actual Revenue (Jul. 30) $3.41B Get Astellas Pharma Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate $0.42 EPSNext Year EPS Consensus Estimate $0.68 EPS Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 10/29/2025(Estimated)--------7/30/2025Q1 2026$0.1356$0.40+$0.2644$0.26$3.20B$3.41B4/25/2025Q4 2025$0.1474$0.27+$0.1226$0.27$3.02B$3.22B2/4/2025Q3 2025-$0.30--$0.36--10/30/2024Q2 2025-$0.13-$0.13-$3.11B8/1/2024Q1 2025-$0.24-$0.35-$3.03B4/25/2024Q4 2024-$0.11-$0.34-$2.79B2/5/2024Q3 2024-$0.12-$0.17-$2.86B11/1/2023Q3 2023$0.17-$0.01 -$0.18-$0.01-$2.71B Astellas Pharma Earnings - Frequently Asked Questions When is Astellas Pharma's earnings date? Astellas Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, October 29th, 2025 based off last year's report dates. Learn more on ALPMY's earnings history. Did Astellas Pharma beat their earnings estimates last quarter? In the previous quarter, Astellas Pharma (OTCMKTS:ALPMY) reported $0.40 earnings per share (EPS) to beat the analysts' consensus estimate of $0.14 by $0.26. Learn more on analysts' earnings estimate vs. ALPMY's actual earnings. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $12.56 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $334.93 million. ALPMY has generated $0.30 earnings per share over the last four quarters. What is Astellas Pharma's price-to-earnings ratio? Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 37.17 and a forward price-to-earnings ratio of 26.55. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $0.42 per share to $0.68 per share in the next year, which is a 61.90% increase. More Earnings Resources from MarketBeat Related Companies INDV Earnings Date NERV Earnings Date SLN Earnings Date CHGCY Earnings Date ZTS Earnings Date DSNKY Earnings Date TAK Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures This page (OTCMKTS:ALPMY) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access